Immunomedics' (IMMU) CEO Cynthia Sullivan on Q2 2017 Results - Earnings Call Transcript

| About: Immunomedics, Inc. (IMMU)
This article is now exclusive for PRO subscribers.

Immunomedics, Inc. (NASDAQ:IMMU) Q2 2017 Earnings Conference Call February 10, 2017 8:00 AM ET

Executives

Michael Garone – Chief Financial Officer

David Goldenberg – Chairman and Chief Scientific Officer

Cynthia Sullivan – President and Chief Executive Officer

Brian Markison – Lead Independent Director

Jason Aryeh – Independent Vice Chairman of the Board and Chairman of the Transaction Committee

Analysts

Boris Peaker – Cowen

Jim Birchenough – Wells Fargo

Matthew Andrews – Jefferies

Nick Abbott – Wells Fargo

Operator

Welcome to Immunomedics, Inc. Second Quarter Fiscal 2017 Results Conference Call. As a reminder, this call is being recorded. Today is Friday February 10, 2017. At this time, I would like to turn the conference over to Michael Garone, Chief Financial Officer of Immunomedics.

Michael Garone

Thank you, Bryan. Before we begin, I would like to inform you that Immunomedics, its directors and certain of its executive officers will be deemed to be participants in the solicitation of proxies from Company’s stockholders in connection with the matters to be considered at the Company’s 2016 Annual Meeting. The Company has filed a definitive proxy statement and form of WHITE proxy card with the SEC in connection with any such solicitation of proxies from Company stockholders. Company stockholders are strongly encouraged to read the definitive proxy statement, including any amendments and supplements, the accompanying white proxy card and any other relevant documents that the company files with the SEC when they become available because they will contain important information.

Information regarding the identity of participants, and their direct or indirect interests, by security holdings or otherwise, is set forth in the proxy statement and other materials filed by the Company with the SEC. Stockholders will be able to obtain the proxy statement, any amendments or supplements to the proxy statement and other documents filed by the Company with the SEC for no charge at the SEC’s website at www.sec.gov. Copies will also be available at no charge at the Company’s website at www.immunomedics.com by writing to Immunomedics, Inc. at 300 The American Road, Morris Plains, New Jersey 07950, or by calling the Company’s proxy solicitor, MacKenzie Partners, Inc., at (212) 929-5500, or by calling Dr. Chau Cheng, Senior Director, Investor Relations & Corporate Secretary, at (973) 605-8200, extension 123.

In addition, I would like to remind everyone that during this call, we will be making forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements may involve significant risks and uncertainties. Actual results could differ materially from those expressed or implied on this call. For factors that could cause such differences, please refer to our regulatory filings with the Securities and Exchange Commission most recently our annual report for the year ended June 30, 2016. The earnings report is available on our Company's website at www.immunomedics.com.

Now, let me turn the call over to our Chairman and Chief Scientific Officer, Dr. David Goldenberg.

David Goldenberg

Thank you, Mike. Good morning everyone and thank you for joining us to discuss our announcement of the Global Licensing Agreement with Seattle Genetics as well as our financial results for the second fiscal quarter of 2017. In addition to Mike Garone with me today are Brian Markison, Lead Independent Director of the Immunomedics Board; and Jason Aryeh, Independent Vice Chairman of the Board and Chairman of the Transaction Committee; as well as Cynthia Sullivan, President and Chief Executive Officer.

Following our prepared remarks today, we will open up the call for questions. Many of you will already have seen copies of the press releases we issued regarding our financial results and the transaction with Seattle Genetics. There is also a presentation accompanying the Seattle Genetics announcement that can be accessed on the Investor Relations page of our website today. Today marks a monumental day for Immunomedics as we announced that we have entered into an exclusive global licensing agreement with Seattle Genetics under which Seattle Genetics will endeavor to fund the development, manufacture and commercialization of sacituzumab govitecan or IMMU-132, a proprietary solid tumor therapy candidate in multiple cancer indications.

The agreement provides for potential payments of approximately $2 billion plus double-digit tiered royalties on global net sales. We are excited about this agreement as it will further advance IMMU-132 on behalf of advanced cancer patients while delivering significant near and long-term value to our stockholders. Seattle Genetics reputation, development portfolio and track record make them an ideal partner to develop and commercialize IMMU-132. We look forward to working with them to bring in IMMU-132 to commercialization.

Additionally this agreement validates the dedication and effort by our entire team. We are proud to have achieved this critical milestone and thank all of our employees, our clinical investigators and their patients. And just over three years of clinical trials involving more than 400 patients with diverse cancers, we have significantly enhanced the clinical development of IMMU-132. We have looked forward to appropriately supporting Seattle Genetics as it seeks to bring IMMU-132 to commercialization.

Before we discuss this agreement with Seattle Genetics in more depth, I would like to turn the call back over to Mike to cover our financial results for the second fiscal quarter of 2017.

Michael Garone

Thank you, David. Total revenues for the second quarter of fiscal 2017 ended December 30, 2016 was $200,000 compared to $700,000 for the same quarter of last fiscal year, a decrease of $300,000 or approximately 43%. The decrease was due primarily to a $300,000 decrease in LeukoScan product sales primarily from a delay in obtaining regulatory approval for new LeukoScan inventory.

Total costs and expenses for the quarter were $15.7 million compared to $16.4 million for the same quarter in fiscal 2016, a decrease of $700,000 or approximately 4%. This decrease was due primarily to $1.5 million reduction in research and development expenses resulting from a $4.6 million reduction in expenses related to the Phase 3 PANCRIT-1 clinical trial, which was terminated during the third quarter of fiscal 2016, and a $600,000 reduction in manufacturing material purchases compared to the same period in the prior year.

These reductions were partially offset by a $3.7 million increase in product development expense related to manufacturing the antibody drug-conjugate IMMU-132 or sacituzumab govitecan. The decrease in research and development expenses was also primarily offset by a $1.1 million increase in general and administrative expenses, due primarily to a $500,000 increase in legal fees and a $900,000 increase in professional fees associated with the proxy contest commenced by venBio Select Advisor LLC, partially offset by a reduction in employee related costs.

The Company recognized a $7.2 million non-cash expense during the three-month period ended December 31, 2016 reflecting the corresponding increase in the fair value of the warrant liability at December 31, 2016 resulting from the increase in the price of our common stock from the issuance date of October 11, 2016.

Interest expense related to 4.75% percent convertible senior notes due 2020 was $1.4 million for both quarters ended December 31, 2016 and December 31, 2015. Including amortization of $200,000 of debt issuance costs in each quarter. There was no income tax benefit for the second quarter compared to a $3.2 million income tax benefit for the same quarter in fiscal 2016, which is related to the sale of a portion of our New Jersey State net operating losses or NOLs and research and development or R&D tax credits.

Net loss attributable to stockholders was $24.4 million or $0.23 per basic and diluted share for the second quarter of fiscal year 2017 compared to a net loss attributable to stockholders of $13.7 million or $0.15 per basic and diluted share for the same quarter in fiscal 2016. That's an increase of $10.7 million or approximately 78%. The increase was due primarily to the increase in the fair value of the warrant liability of $7.2 million. The receipt of proceeds from nonrecurring $3.2 million net operating losses in R&D tax credit sale in 2015 and the $1.1 million increase in general and administrative expenses primarily attributable to the proxy contest commenced by venBio partially offset by a $1.5 million decrease in research and development expense.

Moving on the six-month report total revenues for the first half of fiscal 2017 were $1.1 million compared to $1.4 million for the same period last fiscal year, a decrease of $300,000 or approximately 21%. The decrease was due primarily to a $300,000 decrease in LeukoScan product sales, primarily from a delay in obtaining regulatory approval for LeukoScan inventory.

Total costs and expenses for the six-month period were $31.4 million, compared to $31.2 million for the same period in fiscal 2016, an increase of $200,000 or approximately 0.6%. Research and development expenses increased $100,000 over the prior year due primarily to an $8.4 million increase in product development expense from manufacturing IMMU-132, which was partially offset by a $7.7 million decrease in expenses related to the early termination of the Phase 3 PANCRIT-1 clinical trial.

General and administrative expenses increased $100,000 compared to the previous year, reflecting a $800,000 increase in legal fees and a $900,000 increase in professional fees associated with the proxy contest commenced by venBio, offset by approximately $1.5 million in adjustments for deferred unearned executive bonuses compared to the same period in the prior year.

Company recognized a $7.2 million non-cash expense during the six-month period ended

December 31, 2016 reflecting the corresponding increase in the fair value of the warrant liability at December 31, 2016 resulting from the increase in the price of our common stock from the issuance date of October 11, 2016.

Interest expense related to the 4.75% Convertible Senior Notes due 2020 was $2.7 million for both periods ended December 31, 2016 and December 31, 2015, including amortization of $400,000 of debt issuance costs in each quarter.

There was no income tax benefit for the six-month period ended December 31, 2016, compared to $3.2 million income tax benefit for the same period in fiscal 2016, which is related to the sale of a portion of our New Jersey State net operating losses or R&D tax credits.

Net loss attributable to stockholders was $40.7 million, or $0.41 per basic and diluted share, for this period, compared to net loss attributable to stockholders of $29.1 million, or $0.31 per basic and diluted shares, for the same period last fiscal year, that’s an increase of $11.6 million, or approximately 40%. The increase was due primarily to the increase in fair value of the warrant liability of $7.2 million and the receipt of proceeds from the non-recurring $3.2 million net operating loss and R&D tax credit sale in fiscal 2016.

Cash, cash equivalents, and marketable securities were $46.6 million as of December 31, 2016. And that summarizes our financial results for the second quarter fiscal 2017 and with that I’ll turn it over to our President and Chief Executive Officer Cindy Sullivan who will continue to discuss our transaction with Seattle Genetics.

Cynthia Sullivan

So thanks Mike. If you're looking at the slides posted to our website, Slides 3 through 6 will begin this discussion. Under our agreement Seattle Genetics will fund the development manufacturing, commercialization of any IMMU-132 in multiple cancer indications. The agreement with Seattle will further advance IMMU-132 on behalf of patients with late stage cancers, who have limited therapeutic options while delivering significant and compelling near and long-term value to stockholders.

As mentioned the global licensing agreement provides for the potential payments of approximately $2 billion including $250 million in upfront cash payments. Plus among other milestone payments an additional $50 million or designated economic split relating to rights outside the U.S., Canada, and the E.U.

The remainder of the consideration comprises approximately $1.7 billion that's contingent upon achieving certain clinical development, regulatory and sales milestones. The agreement also includes double-digit tiered royalties on a global net sales. The risk adjusted pretax net present value or NPV of the transaction is approximately $1.4 billion.

Concurrent with the transaction Seattle Genetics purchasing 3 million shares of common stock, representing an approximate 2.8% stake in Immunomedics at an per share price of $4.90, which represents a 10% premium to Immunomedics 15 trading day volume, weighted average trading stock price for the period ended at the close of trading February 09, 2017, which is the last trading day prior to entering into the global licensing agreement.

Seattle Genetics also has been granted a 3-year warrant to purchase 8,655,804 shares of common stock, which shall be exercisable when the Company has sufficient authorized shares of common stock to enable the full exercise of the warrant such that it will hold up to a 9.9% stake in the company. To receive the second tranche of equity stockholders will be required to approve a proposal at the 2016 annual meeting to increase the Company's authorized share capital.

We believe Seattle Genetics equity investment demonstrates their confidence not only in IMMU-132, but in our remaining clinical and pre-clinical pipeline. The transaction also provides significant upside to our stockholders. The remainder of consideration comprises an additional 50 million or designated economic splits related to rights outside the U.S., Canada and EU and approximately $1.7 billion contingent upon achieving certain clinical, development, regulatory and sales milestones, including the anticipated near-term milestone for acceptance of an initial Biologics License Application or BLA for triple-negative breast cancer indication by the U.S. Food and Drug Administration and future development and regulatory milestones for each additional indication beyond TNBC.

As part of this agreement Immunomedics will also retain the right to elect, to co-promote IMMU-132 in the United States by participating in 50% of the sales effort. Looking ahead, the Seattle Genetics transaction is expected to close this quarter, subject to Hart-Scott-Rodino clearance or early expiration and other customary closing conditions. Under the agreement Immunomedics is also permitted for a limited period of time through February 19, 2017 to continue negotiating with a limited number of parties that previously expressed interest in licensing IMMU-132.

Seattle Genetics has the right to match any subsequent financial superior offer. If they decide not to match, Immunomedics has the right to accept the superior offer and terminate the proposed development and licensing agreement upon payment of a termination fee to Seattle Genetics.

Upon completion of the transaction each company will appoint representatives to serve on a joint steering committee that will be responsible for guiding the overall development, commercialization and the intellectual property strategy for IMMU-132 which will be chaired by a representative from Seattle Genetics.

Turning to Slide 7, let's now discuss what the agreement was Seattle includes. First, while many of you likely know Seattle Genetics, let me highlight that they are an industry leader in developing and commercializing antibody drug conjugates or ADCs. To that end we believe Seattle Genetics is the right partner because they're interested in multiple indications for IMMU-132 and they're including triple-negative breast cancer or TNBC, urothelial cancers or UC, small-cell lung cancer or SCLC, non-small cell lung cancer also called NSCLC and other solid tumors being studied in ongoing clinical trials.

Our companies will work together to initiate the Phase 3 clinical trial of IMMU-132 in patients with TNBC and Seattle Genetics will be submitting a Biologics License Application or BLA to the FDA for the potential, accelerated approval of IMMU-132. We believe we’re on track to achieve these milestones in mid-2017 which could result in an FDA approval and commercial launch of IMMU-132 for TNBC patients in the near term.

We expect IMMU-132 will become a high priority program for Seattle Genetics. They intend to develop and commercialize IMMU-132 globally and multiple indications beyond TNBC, all of which will provide benefits to late stage cancer patients around the world and at the same time provide value for Immunomedics stockholders.

Moving to Slide 8 to Slide 10, we provide additional background on Seattle Genetics and why we believe they are the right partner to commercialize IMMU-132. As I mentioned, they are an industry leader in ADCs which is a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. They have a reputation as one of the most successful and well financed standalone ADC company with a deep product pipeline designed to address unmet medical needs, including follow-on indications for ADCETRIS, its commercial product in collaboration with Takeda Pharmaceutical Company, which is available in more than 65 countries and is in more than 70 clinical trials.

Among other, Seattle Genetics also has an ADC targeting CD33 which is being evaluated in a pivotal Phase 3 CASCADE Trial for acute myeloid leukemia, as well as several additional Phase 1 and Phase 1/2 clinical trials. Seattle Genetics has strong clinical development capabilities in hematologic malignancies and solid tumors, as well as regulatory accomplishments in expanding indications for ADCETRIS. Seattle Genetics has strong expertise and is well positioned to expand into solid cancers with IMMU-132. Our agreement provides substantial upfront cash and what’s unique among the numerous interested parties in that they are committed to commercializing IMMU-132 for the broadest possible range of indications.

Furthermore, Seattle Genetics has an existing marketing and sales organization and infrastructure established in the United States for its current ADC to serve as a foundation for expansion to solid cancer indications. Additionally, they've begun building and marketing a sales organization in the European Union which is targeted to timely support the potential launch of IMMU-132 in this territory. All of these exciting opportunities provide our stockholders with the greatest upside potential to maximize the long-term value opportunity.

So now let me return to Mike, who will discuss the immediate benefits to Immunomedics’ financial profile.

Michael Garone

Thank you Cindy. Starting on Slide 12, as of the end of Immunomedics’ second fiscal quarter of 2017, the company had approximately $47 million in cash on hand. With the $250 million from the up front cash consideration provided by Seattle Genetics for U.S., Canada and EU rights and the additional $15 million equity investment, the transaction significantly enhances the Company's financial profile, providing an immediate boost to liquidity which including the proceeds from the potential warrant exercise totals approximately $354 million excluding transaction-related expenses. The $250 million of upfront cash is currently valued at $2.12 per share.

We estimate the risk-adjusted pretax net present value of the base case of contingent payments from the Seattle Genetics deal at approximately $9.40 per share by transferring responsibility for the IMMU-132 program to Seattle Genetics. We will also immediately reduce our cash burn while receiving rights to future milestone payments.

Looking at Slide 13 beyond IMMU-132, we continue to believe our remaining clinical pipeline is advanced, robust and promising. We highlight that full portfolio again on Slide 13. We have one agent in Phase 3 confirmatory trials and two others besides IMMU-132 in Phase 2 clinical trials. Our lead Independent Director, Brian Markison will now discuss the robust strategic process that brought us to this monumental agreement. Brian?

Brian Markison

Thanks Mike. On Slides 15 through 18, we provided thorough detail of the comprehensive process undertaken by the Board. The agreement with Seattle Genetics follows a robust strategic process with many parties that began more than a year ago before being restarted with the engagement of our outside financial advisor Greenhill and Company.

Regarding our original strategic process, we’ve retained a financial advisor in December 15 with a mandate to explore a licensing deal. Along with the Board the financial advisor conducted outreach to 30 parties signing 22 non-disclosure agreements or NDAs and were different levels of due diligence. We made progress and received non-binding term sheets but the process didn't move meaningfully forward, ultimately culminating in the Company's decision to allow the engagement with the financial advisor to expire.

The resulting gap in time while the engagement expired led to speculation in the market about challenges to the clinical and CMC development of 132. In September of 2016, the Company engaged Greenhill to explore a range of strategic and business opportunities including a licensing or sale of IMMU-132, as well as a sale of the entire company. We’ve retained Greenhill on the basis of its reputation and global capabilities in biopharmaceutical M&A and licensing transactions. Greenhill spent months preparing the company and management including asking for an independent third-party commercial assessment and an independent third-party CMC audit and assisting the company in selecting the consultants that would conduct these third-party analysis and audits.

Additionally, Greenhill undertook extensive preparation work for the process including the creation of non-confidential and confidential summaries marketing materials on recent developments and clinical updates. Greenhill also assisted the company on the creation of a robust confidential data room and in the preparation for dialogue on clinical CMC regulatory and intellectual property functional areas. Greenhill contacted 45 total parties and move forward in advance diligence with 18 parties.

Slide 17 details the depth of diligence that was made available across all functional areas clinical, CMC, regulatory, IP and commercial. Depending on the functional area the diligence include making available detailed area specific decks, access to raw clinical data and correspondence with key regulatory authorities. Together with Greenhill, we completed multiple rounds of Q&As and follow up calls or on site visits in terms of reverse due diligence parties were also asked to present to Immunomedics on their capabilities.

We provide overall highlights of the strategic process on Slide 18. It lasted more than 13 months and involves more than 45 parties being contacted with 33 of them receiving detailed diligence information under a confidentiality agreement. All appropriate parties were contacted and importantly no parties cited management as a reason to refrain from engaging and moving forward toward a transaction.

For the avoidance of doubt and to clarify, no 20% partnership royalty payment is due to Dr. Goldenberg from licensing this asset. The strategic process was exhaustive, competitive and complete. Several parties completed advance diligence including CMC, regulatory and clinical and commercial deep dives and submitted term sheets. Seattle Genetics was involved in the first process but reengaged in late 2016. Given its desire to consummate a transaction quickly, we are pleased to have negotiated modified go-shop under which Immunomedics has the right to continue negotiating with a limited number of parties that previously expressed interest in licensing IMMU-132 until February 19.

Please note that we don't intend to comment on that continued process unless an agreement is entered into with an alternative third-party that the Board teams is financially superior to the agreement with Seattle Genetics. And that Seattle Genetics chooses not to match such offer.

I will now turn it over to Jason Aryeh, our Vice Chairman to discuss the Transaction Committee of the Board and its role in the strategic process. Jason?

Jason Aryeh

Thanks Brian. Looking at Slide 20, Greenhill and Company reports directly to the Transaction Committee of the Board, which I chair and is composed exclusively of the company’s five Independent Directors. The transaction committee was constantly kept appraised at the outreach program and approach and we are actively involved in negotiating term sheets and contracts. Regarding our timing of reaching and announcing this agreement. The Transaction Committee unanimously agreed as fiduciaries that their duty was to do the right thing for our shareholders irrespective of the noise of the ongoing proxy contest with one of our stockholders.

It is crucial to recognize that the Transaction Committee was also unanimously saying they would never rush a deal to conclude a strategic process prior to the annual meeting of stockholders and additionally that the committee would not led a great transaction go due to the coming annual meeting. Additionally, we demanded a modified go-shop in the agreement with Seattle Genetics as a way to ensure competitive process and allow other parties to put forward a superior financial proposal. That provision is very rare in biopharma licensing deals

On Slide 21 we provide a few reasons that the Transaction Committee evaluated in choosing whether to out license IMMU-132 or commercialize it internally. First R&D is Immunomedics core competency not commercialization. The company has no commercial infrastructure, so we would need to build a commercial arm from scratch including marketing, sales, logistics, and commercial manufacturing to commercialize IMMU-132 on a global scale.

To do this, the company would have to raise a very significant and highly diluted additional capital, at a more onerous cost than commercial bio pharmaceutical companies. And even if the company developed a commercial infrastructure successfully, we still estimate it would take the company longer to bring IMMU-132 to market itself, affecting shareholder value and the prospects for cancer patients.

Most successful companies transitioning from R&D to commercialization do so through a strategic partnership like ours with Seattle Genetics. Commercializing internally is generally accepted to be a high risk approach. The Transaction Committee worked with Greenhill on an analysis of what commercializing IMMU-132 internally would inhale.

By our projections, the company would need to immediately raise $150 million to cover the Phase 3 trial for IMMU-132 in TNBC patients and to advance IMMU-132 through the clinical process in other indications and to scale up manufacturing. The company would then need to raise an additional $125 million to build out a sales force and other functions to support marketing initiatives at launch.

To sum it up, the Transaction Committee conducted a financial analysis and the risk reward of a go-it-alone commercialization strategy was not at all encouraging, especially considering the very significant dilution that our stockholders would incur. The Transaction Committee also conducted analyses at more aspirational fund raises and the risk reward calculation did not materially change.

Our dual goal has always been to maximize stockholder value and get IMMU-132 to cancer patients as fast as possible. We believe the deal with and the support of Seattle Genetics will make these a reality. The Board continues to remain engaged in evaluating opportunities to maximize value for the remaining aspects of our clinical portfolio. This agreement with Seattle Genetics will absolutely not halt that process.

Turning to Slide 22, let me now review the plan for allocating the proceeds from this agreement. Upon closing of the transaction the Immunomedics’ Board and Management will evaluate the priority of existing clinical programs, long- and short-term funding needs, a budget for the remainder of 2017 and potential tax efficient ways to return capital to shareholders. We expect this transaction to support the company's liquidity needs, such that Immunomedics can fund itself. And this removes any financing overhang on the stock for the foreseeable future. We look forward to updating you all once a final determination on the use of proceeds has been made.

Finally, we are providing an update on the ongoing proxy contest. As part of the announcement with Seattle Genetics, we will be postponing our annual meeting of stockholders by just two weeks to March 3, 2017. The record date will remain January 24, 2017. The postponement will allow time for the company to complete the modified go-shop period and for our stockholders to appropriately consider the transaction with Seattle Genetics.

The Seattle Genetics transaction also requires Immunomedics to issue shares to them at a premium. And one of the proposals to be voted on at the annual meeting will be an increase in the authorized shares of IMMU. We urge stockholders to approve this proposal so that Immunomedics can receive the second tranche in cash consideration from the transaction.

With that, I will turn it back over to Cindy for closing remarks.

Cynthia Sullivan

Thank you, Jason. As you’ve heard from our Board and Management team, we’re excited about this agreement with Seattle Genetics. We believe that our agreement supports our timeline for initiating a Phase 3 trial and filing for accelerated approval in the TNBC indication in the near-term.

Given Seattle Genetics’ equity investment in our company, we believe our interests are aligned in commercializing IMMU-132 for triple-negative breast cancer patients and advancing it through clinical trials and regulatory approval for all additional indications. I speak on behalf of the entire Board and Management team. When I say we're confident that this agreement with Seattle Genetics will further advance IMMU-132 and deliver significant and compelling near- and long-term value to stockholders.

So thank you for taking the time to join us today. And with that, we’ll open it up to Q&A. Operator?

Question-and-Answer Session

Operator

Thank you. [Operator Instructions] Our first question comes from the line of Boris Peaker from Cowen. Your line is now open.

Boris Peaker

Good morning and congratulations on the transaction.

Cynthia Sullivan

Thank you.

Boris Peaker

My first question is about timing. I'm sure investors will have a lot of questions regarding it. I mean, you mentioned in the opening remarks that transaction was not rushed, specifically for the shareholder meeting. But then why would you leave this go-shop agreement with about a week and a half timing left? So why not just let everybody submit their final offer and kind of completely finalize the best bidder and announce it then.

Cynthia Sullivan

Sure. So Brian, do you want to comment on that further?

Brian Markison

Yes, happy to. In fact a go-shop provision in licensing deals is very rare. Given the scrutiny that we're under and given the process that we're going through within bio, we did the most shareholder-friendly transaction at the time that we could. And as you can imagine it was not received extremely well all around the horn, but we felt for our shareholders, it was absolutely important to have that capability.

Boris Peaker

Got you. And also in terms of structures transaction, you obviously need a shareholder approval to issue the shares. What happens if you don't get the shareholder approval? What happens with the rest of the deal?

Brian Markison

The deal stays intact to the shareholder approval for the shares to be clear, has nothing to do with the rest of the transaction.

Boris Peaker

But if you can't provide the shares to Seattle Genetics, that doesn't somehow reverse the deal?

Brian Markison

Not at all, completely separate from the licensing transaction itself.

Boris Peaker

Got you. And just on Seattle Genetics themselves, certainly, obviously they have expertise in ADCs and they're one of the leading companies in ADCs. I just wanted to understand, you mentioned that you would need to raise about $150 million for development, another $125 million to build a sales force. So why is Seattle Genetics the best partner considering that they aren't profitable yet and they don't have a solid tumor sales force either?

Michael Garone

Let me – I'll start and then bounce it back over to Cynthia and David. I mean number one, they know this technology inside it out. It's the basis for their company in fact. Number two, they're already in the field in the market with a great capital structure. And more importantly, they do not have competing assets in their portfolio with this product. So a lot of other potential parties we spoke to when you get into lung cancer, it's a very competitive field. Cynthia you want to add to that?

Cynthia Sullivan

Yes. I think their reputation in developing and very successfully marketing, their lead ADC makes them one, attractive; two, certainly expansion into solid tumor therapy can one build off the foundation they've already built with the existing salesforce. And then continue to expand on a global front, which they're already working very diligently on for the EU market.

Michael Garone

Cynthia, let me ask Jason to add in on this, because it's a great question and I want to make sure we give the most complete answer possible. Jason?

Cynthia Sullivan

Sure.

Jason Aryeh

Sure, thanks. So couple things, first of all in response to your first question, we did exactly that. We allowed all parties to come in and give their best offer and Seattle Genetics unequivocally had the best offer. So what we're doing is frankly bending over backwards here. And something fairly extraordinary in a licensing transaction to get a good shot for it. So we're trying to do everything in our power for our shareholders.

Additionally, I think what we're Brian said about Seattle Genetics became exquisitely clear for our transaction committee. And that was that a lot of major pharmaceutical companies, global companies had multiple competing solid tumor oncology programs. So a lot of them were very interested in TNBC for example where there is no other competing drug. But as Brian said, had competitive products for be at small cell, non-small cell, you see another indications that we believe and you want 32 will be effective in and that Seattle Genetics will exploit.

So when you look at the value of the transaction, there is tremendous value in milestones and royalties here. And the more different indications that are really pursued here by Seattle Genetics or by any company with which we partnered or sold these assets to the better for our shareholders. And it became crystal clear to us as a transaction committee that for that reason for the lack of competitive solid tumor agents either commercially or in late stage and their expertise in ADC and frankly it's a wonderful organization that became clear to us too in negotiations. This was truly the ideal partner. Although I completely understand your question, might not seem that way at first glance, but it crystallized for us as a transaction committee.

David Goldenberg

This is David Goldenberg. I'd like to add something to the other comments. What is unique for us given our knowledge in our enthusiastic development of this product is our ability to collaborate with Seattle Genetics in continuing the Phase 2 trial that we started, we call the basket trial in which we studied many different indications or cancer types and then focused on triple-negative breast, lung, and Urothelial et cetera. And we are able in this arrangement to continue that study and provide the information to our partner. So that we can jointly discuss how we advance these indications as quickly as possible. That is a very unique opportunity for us to insist and collaborate with our partner.

The other point I would like to make is sort of more personal. We go, we went through an exhaustive very expensive process over a long period of time where many companies as was mentioned due diligence on all aspects of our program, of our product and so and so. But during that process, they not only learn about our product, but we learn about the company and its capabilities in various areas regulatory, scientific and manufacturing. And we were very impressed with the depth and the capabilities of Seattle Genetics in getting to understand the value of IMMU-132, which convince those as a group, yes, they would be able to work with us and advance this product as quickly and efficiently as possible in more than one indication.

And most importantly, this became and will become I believe a high priority development program to Seattle Genetics, which is really what we as a developer of this product and our commitment to bringing it to cancer patients value very highly.

Boris Peaker

Thank you for the very detailed explanation. And just my last question before I jump of the line is, obviously it is a very important transaction for shareholders and very high profile and very closely watched. I was just curious with the Annual Meeting just you formally planned right on the horizon. Why not let maybe shareholders vote on this deal particularly again given this high profile.

Jason Aryeh

Yes. I mean that…

Michael Garone

Go ahead Jason.

Jason Aryeh

You don't venBio I believe pointed out in one of their releases. You don't put such licensing transactions to a vote, right. No, virtually no partner would allow you to do that. So I think we made a Herculean effort frankly on behalf of our shareholders to get this go shop provision in a licensing deal. I think that's extraordinary. And let's make it clear, we did not drive the timing of this process. I hope we made that clear in all of our communications. This was a Seattle Genetics driven timeline. And we are not going to walk away from a great deal for our shareholders for any reason other than what's going to create the most value. That is our fiduciary duty, as directors we take that fiduciary duty extremely, extremely personally.

And everyone on this board was simply focused on doing the best transaction for our shareholders. At whatever time that came about and if that didn't come about until after the meetings then so be it, and if it never came about and the best thing to do was to go, go it alone. Then we would – we were certainly willing to do that, but we did an exhaustive analysis of go it alone as I mentioned in my script versus taking a look at it with this transaction. And it is overwhelmingly more positive to have done this transaction, which I think frankly it’s a fairly extraordinary deal.

Boris Peaker

Thank you very much for a very detailed answer to my questions, and again congratulations on the transaction.

Jason Aryeh

Pleasure, thanks.

Cynthia Sullivan

Thanks.

Operator

Our next question comes from the line of Jim Birchenough from Wells Fargo. Your line is now open.

Jim Birchenough

Yes, hi guys. A few questions just to follow-up on Boris’s question. I guess just in terms of the royalty rate payable, could you let us know with a little more specificity what that rate is. And when you say this was the best deal that was offered in what respect was – I want to just going to sense of what you were focused on there. And did anyone offer better back end economics and was there any offer to acquire the company out right, and then I’ve got two follow-ups.

Brian Markison

Okay, this is Brian. I think that was five questions in one. I’ll start off with the answer and then I’ll turn it over to Jason. On the clarity around the royalty at this time beyond the materials that we have posted and put out already, we’re not going to provide for the clarification on the financial arrangement between the two companies. So I apologize for that but at this time, we’re just going to have our published material stand. As far as the process is concerned we have had a very thorough extremely robust process as Jason has said many times.

There has been a lot of conversation around, should this be a full company deal or a licensing deal with various parties. And I think where we ended up is in the right place, because there is still significant value left behind in Immunomedics that transcends IMMU-132, which is just one program. There are many more programs behind it. And at this time, we felt, it was best to out license the flagship. And then leave the core technology still within the company. So Jason you want to add to that. I know I didn’t answer half his questions yet.

Jason Aryeh

Yes. So, Hey, Jim. So let me be exquisitely clear. We were receptive and we, I mean, not only our transaction committee, but the entire board including management, was extremely receptive to a complete company take out if that was the best deal for shareholders. So there was nothing that was eliminated here I think that might have been your first question. Everything was on the table that was a mandate was given to Greenhill unequivocally. And we were and would always be as a public company, I’d say you’re always for sale, okay.

Okay, so there was no particular thing we were looking for. We were looking for the deal that would maximize value for shareholders. And that had to deal with multiple things, the financials, and what could be the downstream financials. Right, if we are all bullish on IMMU-132, which I believe I know we are internally and I believe our shareholders are as well. Then we wanted to play significantly in the downstream economics here.

So we didn’t give this product away and just to take a significant up front and not participate in the downstream economics, we’re participating handsomely there. What we’ve said is double-digit tiered royalties. Unfortunately, legally that is what we are restricted to at this time more information on the deal will come out early next week. But we evaluated everything, Jim, and we will continue as a board to evaluate everything that comes in for assets beyond IMMU-132, which there is interest.

Jim Birchenough

And just, I guess another multi-part question, but the Seattle Genetics have the opportunity to go to FDA just to have their own discussions. On the accelerator approval process to make sure, there’s a meeting of the minds given that they’re going to be responsible for the filing. And then I also wanted to ask there was that the time of the San Antonio Breast Cancer Symposium talk of – there had been a submission for publication of the triple-negative breast cancer data and at the time it was characterized as uncertain as to whether that was going to come before San Antonio Breast or not. Your prospective partners get to review that transcript and when will we see that publication.

Brian Markison

All right. So on – part of the question, the interaction with Seattle is seamless with respect to the FDA. They have seen everything including the minutes of the FDA communication and they are completely on board with the strategy that the company has set forth, another key part of the decision to work with them. They now will be running the show and they will take it over on a transition basis in the beginning and then they’re going to run with the program. There is no disagreement between the parties on this. I want to be clear it’s a seamless meeting of the minds here where they are just going to go forward and accelerate the programs. With respect to San Antonio, Cindy, do you want to comment on that?

Cynthia Sullivan

Actually with the publication I’ll flip it over to David, who has some comments on that.

David Goldenberg

Well the article in press. I can’t give the date of appearance because that’s up to the journal and because of the embargo requirements of the journal I can’t mention the journal at the present time, but I’m very pleased that it went through a good review. And it, I hope you will agree, Jim that is a solid paper and you’ll see all the confidences that builds your desire in the paper.

Jim Birchenough

Great. Thanks for taking the questions guys.

Operator

[Operator Instructions] Our next question comes from the line of Matthew Andrews from Jefferies. Your line is now open.

Matthew Andrews

Thank you, good morning. Congratulations Cindy and David.

Cynthia Sullivan

Hey, thanks, Matt.

Matthew Andrews

Yes. So couple from me. What’s your view how serious the other potential partners are who you will be meeting with through the end of February.

David Goldenberg

We know they’re extremely serious, we’re not going to comment on the degree of seriousness, nor on the process going forward with them. That’s highly confidential.

Matthew Andrews

Brian, Jason, were there any offers to acquire the company and I assume if so they were deemed less beneficial to shareholders based on the deal today. But were there any offers to acquire the company.

Brian Markison

There has been a lot of conversation about that. We’re not going to get into specific offers of any kind including licensing. It’s something that we considered quite heavily. And again we drove the process to the best transaction we believe possible for the company. Remember there’s a lot of a technology within the Immunomedics. And we thought it was best if people focused on the primary asset in question. And that would drive the most competitive process. And look, but publicly traded if somebody wants to come over the Wall they are free to do so right.

Jason Aryeh

Yes, I’ll just add to that, look we again – we unequivocally did the best deal available unequivocally, okay. So if there was a take out offer for the company that was better in a risk reward way, we absolutely would have taken it. If there’s one in the future, tomorrow or any time thereafter we will absolutely take it. So we took again, unequivocally the best offer that we’ve out there with what we’ve truly believe is the best partner available.

Remember whether it’s a licensing agreement or an acquisition and we were completely receptive to both. If a partner sees IMMU-132 as a triple-negative breast cancer drug and they have other competing agents for the other potential indications here. They’re going to value IMMU-132 and thus the company at a lower valuation than Seattle Genetics, which views this as a pipeline within a drug as they have told us. So we believe we put it in the best hands in the best ADC Company and in a company that will exploit the most indications for both cancer patients and critically for our shareholders.

Matthew Andrews

Thank you, Jason. Cindy, can you conform you’ve met your timeline and submitted the CMC greeting book to FDA in late January as you discussed three weeks ago.

Cynthia Sullivan

I can confirm that, Matt.

Matthew Andrews

And is the FDA meeting on track for late February as discussed a few weeks ago.

Cynthia Sullivan

I can confirm that as well. Things are moving according to the plan and the schedule that the FDA has given the company.

Matthew Andrews

And then in light of the fact yet to set up the steering committee will Seattle Genetics be participating in that meeting.

Cynthia Sullivan

Absolutely, they will be participating and of course they have already reviewed all of the company’s filings related to CMC in terms of a briefing document.

Matthew Andrews

And then what gives you confidence in your manufacturing timelines, ability to start Phase 3 by early April and complete the BLA by mid-year late July or early June. I’m sorry late June, early July.

Cynthia Sullivan

So with regard to manufacturing things are going exactly according to the timeline. We have made clinical batches as well as designated commercial batches. And we’ll continue to manufacture throughout 2017 to support a potential launch under an accelerated approval.

David Goldenberg

Hey, Matt maybe I could just jump in quickly.

Matthew Andrews

Sure.

David Goldenberg

To reiterate what Brian said. This is Seattle Genetics program now. Okay, they are leading from this day forth they lead this program. So we will obviously be collaborative and we are on a joint steering committee. But this is their program to lead no longer Immunomedics program to lead.

Matthew Andrews

Okay, thank you. Cindy, how is the proposed transaction effect the ongoing CEO succession plan, are you still expecting to stand down after BLA filing that part of the year?

Brian Markison

Cindy, not to put you on the spot but if you don’t mind, I feel that the CEO succession plan is continuing as we’ve previously stated. And now with the licensing deal complete it also helps us narrow our filters for the proper succession candidate. But in the mean time we’ve got every confidence and Cynthia to help during the transition period and provide the great leadership that has gotten us to this point.

Jason Aryeh

Yes, Matt we don’t say something and then not do it, okay. So whatever we’ve said we’re going to do. And Cindy and David were essential extremely cooperative and very helpful to this process of – this what I think it’s a tremendous licensing transaction with Seattle Genetics.

Matthew Andrews

Brian and Jason thank you for the clarity there. just one last one for me then, appreciating its now Seattle Genetics program, what’s the expectation Cindy if you can talk about this when the last patient rolled will have competed their second confirmatory scan is that looking like a late April timeframe. And I just actually – and that’s major data update presumably be at ASCO. So what can you say relative to the timing of last patient second scan.

Cynthia Sullivan

Yes, so your spot on there Matt, the company announced that we completed enrollment of 100 patients, at the end of last year. So you are right, according to CT scanning it would be sometime in the April timeframe for the confirmatory.

Matthew Andrews

Okay, thank you. Congrats, again.

Cynthia Sullivan

Thanks, Matt.

Operator

Our next question comes from the line of Nick Abbott from Wells Fargo. Your line is now open.

Nick Abbott

Good morning. Thanks for taking my question. Just a quick one and it relates to the right to co-promote. Can you just elaborate what your sources are on that and how that might affect the value coming from obviously failed in U.S. territory? Thank you.

Brian Markison

Yes, this is Brian. We think the co-promote has immense value to the company. Again, should we elect two co-promote. It will help the company build out of it’s infrastructure in the future to promote some of its own candidates coming through the pipeline. And also to take part with Seattle Genetics and driving the top line growth for IMMU-132. So from our perspective its pure opportunity that will help the company in the future and it’s a great way to build a commercial organization when you don’t have one through participation with another company that’s already doing a great job in the marketplace.

Nick Abbott

That it doesn’t affect the royalty rates so there is no profit share.

Jason Aryeh

Absolutely, no effect to the royalty rates or profit share whatsoever.

Nick Abbott

Okay. Thank you.

David Goldenberg

And I think it’s important to note also there that it gets paid for by another party. Right, so our shareholders are not – having to be diluted to build out a commercial infrastructure.

Operator

I’m showing no further questions. At this time I would like to hand the conference back over to Cynthia Sullivan for her closing remarks.

Cynthia Sullivan

So thanks very much to all of you for joining us on this very exciting morning. And on behalf of the entire management team, I’d also like to thank you for your continued support and your interest in Immunomedics. Have a good day.

Operator

That does conclude today’s conference call. You may now disconnect. Thanks and have a great day.

Copyright policy: All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.

THE INFORMATION CONTAINED HERE IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL, CONFERENCE PRESENTATION OR OTHER AUDIO PRESENTATION, AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION, THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE AUDIO PRESENTATIONS. IN NO WAY DOES SEEKING ALPHA ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S AUDIO PRESENTATION ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

If you have any additional questions about our online transcripts, please contact us at: transcripts@seekingalpha.com. Thank you!